tradingkey.logo

Portage Biotech Inc

PRTG
6.810USD
0.000
Close 12/19, 16:00ETQuotes delayed by 15 min
11.26MMarket Cap
LossP/E TTM

Portage Biotech Inc

6.810
0.000
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Portage Biotech Inc

Currency: USD Updated: 2025-09-03

Key Insights

Portage Biotech Inc's fundamentals are relatively very healthy, Its valuation is considered fairly valued, Institutional ownership is very high.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Portage Biotech Inc's Score

Industry at a Glance

Industry Ranking
320 / 689
Overall Ranking
493 / 4737
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Portage Biotech Inc Highlights

StrengthsRisks
Portage Biotech Inc. is a clinical-stage immuno-oncology company. The Company is engaged in advancing therapies to improve long-term treatment response, and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of four platforms, with lead programs consisting of invariant natural killer T-cell (iNKT) engagers and a suite of treatments targeting the adenosine pathway. Within these four platforms, the Company has nine product candidates, of which five are pre-clinical and four of which are clinical stage. The Company’s portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent targeting the adenosine pathway.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 346.59.
Undervalued
The company’s latest PE is -1.19, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 896.23K shares, increasing 25.75% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-03

The current financial score of Portage Biotech Inc is 7.04, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score
7.04
Change
0

Financials

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

Operational Efficiency

Growth Potential

Shareholder Returns

Portage Biotech Inc's Company Valuation

Currency: USD Updated: 2025-09-03

The current valuation score of Portage Biotech Inc is 1.20, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.29, which is -94.05% below the recent high of -0.08 and 19.43% above the recent low of -1.04.

Score

Industry at a Glance

Previous score
1.20
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 320/689
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-09-03

No earnings forecast score is currently available for Portage Biotech Inc. The Biotechnology & Medical Research industry's average is 7.96.

Score

Industry at a Glance

Previous score
0.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.
No Data

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-03

The current price momentum score of Portage Biotech Inc is 4.40, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 9.97 and the support level at 5.02, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
3.69
Change
-0.13

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(3)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.544
Neutral
RSI(14)
41.827
Neutral
STOCH(KDJ)(9,3,3)
4.373
Oversold
ATR(14)
0.934
Low Volatility
CCI(14)
-53.785
Neutral
Williams %R
99.655
Oversold
TRIX(12,20)
0.423
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(5)
Neutral(0)
Buy(1)
Indicators
Value
Direction
MA5
7.120
Sell
MA10
7.771
Sell
MA20
8.302
Sell
MA50
6.855
Sell
MA100
7.479
Sell
MA200
6.105
Buy

Institutional Confidence

Currency: USD Updated: 2025-09-03

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Compedica Holdings, Ltd
625.00K
--
Bailey (Gregory Hugh)
467.80K
-8.06%
Mellon (James)
239.54K
-13.40%
SalvaRx Group Plc
35.66K
--
QTR Family Wealth, LLC
19.27K
--
Bison Wealth, LLC
19.27K
-80.44%
Mintz (Steven Michael)
7.00K
+153.07%
Kramer (Robert)
5.04K
-28.41%
BlackRock Institutional Trust Company, N.A.
348.00
--
1
2

Risk Assessment

Currency: USD Updated: 2025-09-03

The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the mixed Biotechnology & Medical Research industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Portage Biotech Inc is 3.09, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. The company's beta value is 0.64. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
3.09
Change
0
Beta vs S&P 500 index
0.66
VaR
+10.44%
240-Day Maximum Drawdown
+70.62%
240-Day Volatility
+259.58%

Return

Best Daily Return
60 days
+23.22%
120 days
+103.82%
5 years
+178.15%
Worst Daily Return
60 days
-11.86%
120 days
-15.52%
5 years
-38.90%
Sharpe Ratio
60 days
-0.32
120 days
+1.25
5 years
+0.22

Risk Assessment

Maximum Drawdown
240 days
+70.62%
3 years
+98.56%
5 years
--
Return-to-Drawdown Ratio
240 days
+0.71
3 years
-0.32
5 years
--
Skewness
240 days
+6.64
3 years
+6.59
5 years
+7.16

Volatility

Realised Volatility
240 days
+259.58%
5 years
--
Standardised True Range
240 days
+14.23%
5 years
--
Downside Risk-Adjusted Return
120 days
+440.26%
240 days
+440.26%
Maximum Daily Upside Volatility
60 days
+114.11%
Maximum Daily Downside Volatility
60 days
+64.83%

Liquidity

Average Turnover Rate
60 days
+9.20%
120 days
+78.11%
5 years
--
Turnover Deviation
20 days
-93.86%
60 days
-87.24%
120 days
+8.32%

Peer Comparison

Biotechnology & Medical Research
Portage Biotech Inc
Portage Biotech Inc
PRTG
3.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
Amicus Therapeutics Inc
FOLD
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
Krystal Biotech Inc
KRYS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
Charles River Laboratories International Inc
CRL
8.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals Inc
MDGL
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQVIA Holdings Inc
IQV
8.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of Portage Biotech Inc?

The TradingKey Stock Score provides a comprehensive assessment of Portage Biotech Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Portage Biotech Inc’s performance and outlook.

How do we generate the financial health score of Portage Biotech Inc?

To generate the financial health score of Portage Biotech Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Portage Biotech Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Portage Biotech Inc.

How do we generate the company valuation score of Portage Biotech Inc?

To generate the company valuation score of Portage Biotech Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Portage Biotech Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Portage Biotech Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Portage Biotech Inc.

How do we generate the earnings forecast score of Portage Biotech Inc?

To calculate the earnings forecast score of Portage Biotech Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Portage Biotech Inc’s future.

How do we generate the price momentum score of Portage Biotech Inc?

When generating the price momentum score for Portage Biotech Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Portage Biotech Inc’s prices. A higher score indicates a more stable short-term price trend for Portage Biotech Inc.

How do we generate the institutional confidence score of Portage Biotech Inc?

To generate the institutional confidence score of Portage Biotech Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Portage Biotech Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Portage Biotech Inc.

How do we generate the risk management score of Portage Biotech Inc?

To assess the risk management score of Portage Biotech Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Portage Biotech Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Portage Biotech Inc.
KeyAI